Roffman Miller Associates Inc. PA Acquires 2,020 Shares of Johnson & Johnson (NYSE:JNJ)

Roffman Miller Associates Inc. PA lifted its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 0.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 263,418 shares of the company's stock after purchasing an additional 2,020 shares during the quarter. Johnson & Johnson comprises approximately 2.8% of Roffman Miller Associates Inc. PA's portfolio, making the stock its 14th biggest position. Roffman Miller Associates Inc. PA's holdings in Johnson & Johnson were worth $43,685,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the stock. Hexagon Capital Partners LLC increased its position in Johnson & Johnson by 1.4% during the first quarter. Hexagon Capital Partners LLC now owns 6,755 shares of the company's stock worth $1,120,000 after purchasing an additional 96 shares during the last quarter. Drake & Associates LLC increased its position in Johnson & Johnson by 54.1% during the first quarter. Drake & Associates LLC now owns 14,896 shares of the company's stock worth $2,470,000 after purchasing an additional 5,227 shares during the last quarter. Traveka Wealth LLC increased its position in Johnson & Johnson by 21.7% during the first quarter. Traveka Wealth LLC now owns 7,749 shares of the company's stock worth $1,285,000 after purchasing an additional 1,382 shares during the last quarter. Tradewinds LLC. increased its position in Johnson & Johnson by 2.4% during the first quarter. Tradewinds LLC. now owns 18,102 shares of the company's stock worth $3,002,000 after purchasing an additional 429 shares during the last quarter. Finally, Cloud Capital Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at $157,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Ratings Changes

JNJ has been the subject of a number of recent analyst reports. Bank of America lowered their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Raymond James Financial dropped their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Eleven analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $171.00.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded down $0.82 during trading hours on Friday, reaching $156.87. 7,866,488 shares of the stock were exchanged, compared to its average volume of 8,066,975. The company has a market cap of $377.44 billion, a P/E ratio of 17.45, a price-to-earnings-growth ratio of 2.15 and a beta of 0.41. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock has a 50 day moving average of $153.75 and a two-hundred day moving average of $154.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.31%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.